This segment focuses on the research, development, and clinical trials of immuno-oncology therapies. Corvus Pharmaceuticals is developing novel product candidates that precisely target proteins critical to the proliferation and survival of cancer cells. Research and development activities include preclinical studies, Phase I/Ib and Phase II clinical trials, and the evaluation of biomarkers. The company utilizes advanced technologies such as monoclonal antibodies and small molecule inhibitors. The primary therapeutic areas are non-small cell lung cancer, head and neck cancers, and various malignant T-cell lymphomas. The goal is to improve patient outcomes by providing innovative treatments that harness the power of the immune system to fight cancer. Market positioning is based on the development of targeted therapies with the potential for improved efficacy and reduced side effects. Future opportunities include expanding the clinical trial pipeline and securing regulatory approvals. Partnerships with companies like Angel Pharmaceuticals support the development of the pipeline.